NCT01916187

Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma

A Pilot Study of Imetelstat Given Intravenously on Day 1 and 8 of a 21 Day Schedule Alone and With Standard 13-Cis-Retinoic Acid in Children With Recurrent and/or Refractory Neuroblastoma

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: NCIC Clinical Trials Group · Network
• Sex: All
• Age: 18 Months – 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the best dose of imetelstat when given alone for patients with neuroblastoma and also when given in combination with 13-cis-retinoic acid.

Detailed description

This research is being done because imetelstat has been shown to slow the growth of tumours in animals and may also be doing so in adults, but we are not sure if it can also slow tumour growth in children and offer better results than standard treatment. Laboratory studies suggest imetelstat may increase the activity of 13-cis-retinoic acid, which is used to treat neuroblastoma, although this is not yet proven in patients.

Conditions

• Neuroblastoma

Interventions

Type	Name	Description
DRUG	Imetelstat

Timeline

• Start date: 2013-07-30
• Primary completion: 2013-11-22
• Completion: 2014-01-16
• First posted: 2013-08-05
• Last updated: 2020-09-21

Locations

1 site across 1 country: Canada